Biosplice Therapeutics Valuation Estimate
Biosplice Therapeutics Valuation as of Last Funding Round
Biosplice Therapeutics Company Overview
Established in 2009 by Osman Kibar, Biosplice's mission is to restore health by providing the finest medicines based on alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization. It enables them to eliminate harmful proteins using small molecules selectively. Biosplice's primary focuses are on treatments for osteoarthritis and oncology. However, they are also in the early stages of developing programs in neurology and other areas.
Biosplice Therapeutics Valuation History
FAQ
Does Biosplice Therapeutics have stock?
Yes, Biosplice Therapeutics and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Biosplice Therapeutics is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Biosplice Therapeutics publicly traded?
No, Biosplice Therapeutics is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Biosplice Therapeutics stock?
As a privately held company, Biosplice Therapeutics shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Biosplice Therapeutics.
What is the stock symbol for Biosplice Therapeutics?
Biosplice Therapeutics is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Biosplice Therapeutics stock on UpMarket?
If you would like to buy shares in Biosplice Therapeutics, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Biosplice Therapeutics stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Biosplice Therapeutics as well.
What is Biosplice Therapeutics stock price?
The stock price of Biosplice Therapeutics can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Biosplice Therapeutics has issued 250 million shares, at the estimated UpMarket valuation of $14.70 billion, each share of Biosplice Therapeutics stock would be worth $58.79.
How do Biosplice Therapeutics pre-IPO trades work?
Pre-IPO trades for Biosplice Therapeutics will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Biosplice Therapeutics doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Biosplice Therapeutics going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Biosplice Therapeutics officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Biosplice Therapeutics should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Biosplice Therapeutics with UpMarket?
Exiting your investment in Biosplice Therapeutics typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Biosplice Therapeutics shares?
If you own Biosplice Therapeutics shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Biosplice Therapeutics?
UpMarket’s valuation estimate for Biosplice Therapeutics is algorithmically generated based on recent primary round financings by Biosplice Therapeutics, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Biosplice Therapeutics could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
UpMarket was founded in 2019 and has helped hundreds of investors access alternative investments. UpMarket is a licensed broker-dealer based in the United States. UpMarket customers have invested over $150 million in pre-IPO companies, hedge funds, private equity, real estate, and other alternatives.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Biosplice Therapeutics,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Biosplice Therapeutics Management
| Name | Position |
|---|---|
| Cevdet Samikoglu | CEO |
| Scott Bulcao | CLO |
| Erich Horsley | CFO |
